Industry News

AMSURG Corp. announced today that it has received the consents necessary to effect certain amendments to its 5.625% Senior Notes due 2022. The Amendments amend the Indenture governing the Notes, dated as of July 16, 2014, by and among AMSURG, U.S. Bank, N.A., as trustee, and certain subsidiaries of AMSURG, as guarantors, to include limited condition acquisition technology, amend the definition of“ Change of Control” contained in the Notes to waive any obligation of..."/>
AMSURG Announces Successful Completion of Consent Solicitation with Respect to 5.625% Senior Notes Due 2022
Xenetic Biosciences, Inc., a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has commenced a collaboration with Excivion Ltd. to develop a vaccine against Zika and dengue viruses. As part of the collaboration, Xenetic’ s proprietary IMUXEN™ Technology will be used to develop the..."/>
Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine
Akers Biosciences, Inc.,, a developer of rapid health information technologies, announces the results of a study of the Company's BreathScan OxiCheck™ test, the first disposable breath test to rapidly determine levels of oxidative stress in the body-- an indicator of the overall health and wellbeing of a person. The study was performed in Philadelphia, PA, under the supervision of Adam C. Sobel M.D., Director, Medical of Akers Bio. The results were highly..."/>
Akers Biosciences Completes Study on First Rapid Breath Test for Oxidative Stress
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration has granted orphan drug designation to the active ingredient dusquetide for treatment of macrophage activation syndrome. Dusquetide has previously received..."/>
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
Immunomedics, Inc. today announced that adding an inhibitor of ATP-binding cassette transporters to sacituzumab govitecan, the Company’ s lead antibody-drug conjugate for solid cancer therapy, increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell line. Results from this preclinical study were published in Molecular Cancer Therapeutics. 1. Sacituzumab govitecan is a first-in-class ADC developed by the..."/>
Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) Activity in SN-38-Resistant Cancer Cells Published
Horizon Pharma plc, a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the United States Patent and Trademark Office has granted a Notice of Allowance for U.S. patent application number 14/ 563,000, entitled "Delayed-Release Glucocorticoid Treatment of Rheumatoid Disease"..."/>
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS® (prednisone) Delayed-Release Tablets
Theratechnologies Inc. today announced that the abstract for the primary end-point results of the ibalizumab phase III study has been selected for a late breaker oral presentation at the IDWeek Conference to be held in New Orleans, LA, from October 26 to 30, 2016. Dr. Jay Lalezari, Medical Director, Quest Clinical Research and an Assistant Clinical Professor of Medicine at the University of California, San Francisco will be presenting detailed data..."/>
Ibalizumab Phase III Study Primary End-Point Results to Be Presented at IDWeek 2016
BD Celebrates 60 Years In Sandy, Utah
Insys Therapeutics, Inc. today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center and is supported by the Canadian Institutes of Health Research and the Company."/>
Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol
Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, has today announced its support of the Difficult Airway Society with the launch of the first research grant directed to ADEPT Guidance. The research grant, which will be funded by Teleflex and administered by the Difficult Airway Society, will support the evaluation of second-generation SADs. While there are both national and international regulations..."/>
The Difficult Airway Society (DAS) Launches Inaugural Project Grant to Support Formal Evaluation of Second-Generation Supraglottic Airway Devices (SADs) in Accordance with ADEPT (Airway Device Evaluation Project Team) Guidance
Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced top-line results from the Phase 3 TACTT2 trial with..."/>
Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
Innovus Pharmaceuticals' recent strong earnings growth, the path forward, and analyst reaction to the company's surge in revenues. The company reported a robust second quarter with $1 million in revenue and positive operational cash flow of $256,000. In addition to exceeding Q2..."/> Innovus Pharma (INNV) Reaches a Positive Cash Flow & Issues Strong Outlook
Sunshine Heart, Inc. announced today that its Chief Executive Officer and Chairman of the Board, John Erb, is scheduled to present at the 2016 investMNt Conference in Minneapolis, MN on August 24 th at 11:45 AM CT.. To access the live webcast, please visit the Investors page of the Sunshine Heart website at cfm. An audio archive of the webcast will be available following the call on the Company’ s website."/>
Sunshine Heart to Present at the 2016 investMNt Conference on August 24, 2016
Prima BioMed Ltd, has provided an update on the Company's cash position and the recruitment progress in its two active clinical trials in IMP321. Financial Position As a result of careful financial management, Prima remains in a solid financial position, with approximately A $20 M cash as of 30 June 2016. Based on the Company's forecasts, the current operational cash reach has been extended well into the fourth quarter of 2017.. Clinical Trial Updates:..."/>
Prima BioMed Ltd: Operational Update
Medtronic PLC is warning doctors worldwide to use extra care when inserting a popular new kind of heart valve in some patients, following reports of 19 deaths from severe blood vessel trauma. In a letter publicized late Tuesday, the Minnesota-run company informed doctors that it is voluntarily updating its instructions for using the minimally invasive EnVeo R delivery system, which doctors use to implant the Evolut R aortic valve in the heart."/>
Medtronic warns doctors on heart valve delivery system after 19 deaths reported [Star Tribune (Minneapolis)]
Acorda Therapeutics, Inc. owns approximately 96.8 percent of all the shares and votes in Biotie. Acorda has initiated redemption proceedings in accordance with Chapter 18 of the Finnish Companies Act in order to redeem all the remaining Biotie shares held by the..."/>
Teva Pharmaceutical Industries Ltd. today announced that the European Commission has granted marketing authorization for CINQAERO ® in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland. CINQAERO ® is a humanized interleukin-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe..."/>
European Commission Grants Marketing Authorization for Teva’s CINQAERO® (reslizumab)
Patanjali Ayurved enters baby care segment [Mint, New Delhi]
Strides Shasun Ltd on Wednesday said its board has approved hiving off its active pharmaceutical ingredient business into a subsidiary to give more focus. "The business requires a different level of focus," Strides said in a statement to stock exchanges,. "With the new set of regulatory and statutory compliance, the commodity API business will need its own leadership team and strategy."/>
Strides Shasun hives-off API business, posts Rs26 crore net profit in Q1 [Mint, New Delhi]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary661 Articles
Information Technology589 Articles
Financials516 Articles
Industrials370 Articles
Health Care354 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at